Japanese breakthrough could counter patent loss for Coloplast
New opportunities in Coloplast’s continence care business in Japan will not have an immediate impact on the business, but it could help the group to maintain growth rates in the long run as other products go off patent, Sydbank analyst Søren Løntoft Hansen believes.
BY LONNI LYNGE
Japanese healthcare authorities paved the way for a commercial breakthrough for Denmark’s Coloplast on the important Asian market this week, as they decided to improve reimbursement for intermittent catheters, meaning the monthly supplement per catheter user will increase with more than 50%.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Coloplast Chief: We delivered a comeback
For abonnenter
Coloplast and Ambu team up
For abonnenter
